TBPH Theravance Biopharma Inc

Price (delayed)

$7.11

Market cap

$522.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.11

Enterprise value

$984.9M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
The company's quick ratio rose by 49% QoQ
Theravance Biopharma's EPS has increased by 11% YoY and by 4.6% QoQ
TBPH's equity is down by 48% year-on-year but it is up by 20% since the previous quarter
TBPH's revenue is down by 16% year-on-year and by 3.2% since the previous quarter
The gross profit has contracted by 16% YoY and by 3.2% from the previous quarter

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
73.47M
Market cap
$522.37M
Enterprise value
$984.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
Earnings
Revenue
$64.16M
EBIT
-$227.06M
EBITDA
-$217.69M
Free cash flow
-$267.09M
Per share
EPS
-$4.11
Free cash flow per share
-$4.07
Book value per share
-$4.6
Revenue per share
$0.98
TBVPS
$6.54
Balance sheet
Total assets
$429.25M
Total liabilities
$729.63M
Debt
$668.31M
Equity
-$300.37M
Working capital
$266.05M
Liquidity
Debt to equity
-2.22
Current ratio
4.96
Quick ratio
4.55
Net debt/EBITDA
-2.12
Margins
EBITDA margin
-339.3%
Gross margin
100%
Net margin
-411.7%
Operating margin
-469.3%
Efficiency
Return on assets
-59.2%
Return on equity
N/A
Return on invested capital
-25.3%
Return on capital employed
-62.7%
Return on sales
-353.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
3.64%
1 week
-15.96%
1 month
-44.45%
1 year
-59.65%
YTD
-59.99%
QTD
-51.03%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$64.16M
Gross profit
$64.16M
Operating income
-$301.11M
Net income
-$264.16M
Gross margin
100%
Net margin
-411.7%
Theravance Biopharma's operating margin has decreased by 29% YoY
Theravance Biopharma's net margin has decreased by 17% YoY
TBPH's revenue is down by 16% year-on-year and by 3.2% since the previous quarter
The gross profit has contracted by 16% YoY and by 3.2% from the previous quarter

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
N/A
P/S
7.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.35
Theravance Biopharma's EPS has increased by 11% YoY and by 4.6% QoQ
TBPH's equity is down by 48% year-on-year but it is up by 20% since the previous quarter
The P/S is 80% lower than the 5-year quarterly average of 35.6 and 53% lower than the last 4 quarters average of 15.4
TBPH's revenue is down by 16% year-on-year and by 3.2% since the previous quarter

Efficiency

How efficient is Theravance Biopharma business performance
Theravance Biopharma's return on sales has decreased by 14% YoY
The ROIC has grown by 12% YoY
The company's return on assets fell by 11% YoY and by 3.5% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 41% less than its total liabilities
The company's quick ratio rose by 49% QoQ
TBPH's current ratio is up by 46% since the previous quarter and by 6% year-on-year
TBPH's equity is down by 48% year-on-year but it is up by 20% since the previous quarter
The debt to equity rose by 32% YoY but it fell by 23% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.